
ACOG
Healthcare · Biotechnology · $182.9M market cap
$8.30-0.26 (-3.0%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +0.4% over 90 days · 30-day revisions 3 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 11, 2026 | After the close | -0.33 | -0.28 | +15.2% |
| Aug 13, 2026 | After the close | -0.39 | -0.40 | -2.6% |
| May 14, 2026 | After the close | -0.39 | -0.32 | +17.9% |
| Mar 27, 2026 | Time not confirmed | -0.27 | -0.31 | -14.8% |
| Nov 13, 2025 | After the close | -0.43 | -0.30 | +30.2% |
| Aug 14, 2025 | After the close | -0.46 | -0.65 | -41.3% |
| May 15, 2025 | After the close | -0.58 | -0.20 | +65.5% |
| Mar 31, 2025 | Time not confirmed | -0.48 | -0.50 | -4.2% |
| Nov 15, 2024 | After the close | -1.00 | -0.31 | +69.0% |
| Aug 12, 2024 | After the close | -1.00 | -0.25 | +75.0% |
| May 15, 2024 | Time not confirmed | — | -0.87 | — |
| Nov 29, 2023 | Time not confirmed | — | -0.86 | — |
| Aug 23, 2023 | Time not confirmed | — | -0.74 |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of…
| — |
| May 31, 2023 | Time not confirmed | — | -0.60 | — |
| Mar 8, 2023 | After the close | -0.75 | -1.25 | -66.7% |
| Nov 28, 2022 | After the close | -1.25 | -1.00 | +20.0% |
| Aug 25, 2022 | After the close | -1.25 | -1.25 | 0.0% |
| Apr 28, 2022 | After the close | -1.50 | -1.75 | -16.7% |
| Nov 30, 2021 | Time not confirmed | — | -2.33 | — |